Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Preclinical models of non-alcoholic fatty liver disease
Prasanna K. Santhekadur, Divya P. Kumar, Arun J. Sanyal
Journal of Hepatology (2017) Vol. 68, Iss. 2, pp. 230-237
Open Access | Times Cited: 328

Showing 26-50 of 328 citing articles:

Generation of Human Fatty Livers Using Custom-Engineered Induced Pluripotent Stem Cells with Modifiable SIRT1 Metabolism
Alexandra Collin de l’Hortet, Kazuki Takeishi, Jorge Guzman‐Lepe, et al.
Cell Metabolism (2019) Vol. 30, Iss. 2, pp. 385-401.e9
Open Access | Times Cited: 86
Ferroptosis mediated by the interaction between Mfn2 and IREα promotes arsenic-induced nonalcoholic steatohepatitis
Sen Wei, Tianming Qiu, Ningning Wang, et al.
Environmental Research (2020) Vol. 188, pp. 109824-109824
Closed Access | Times Cited: 84
Drug-induced liver injury in obesity and nonalcoholic fatty liver disease
Julien Allard, Dounia Le Guillou, Karima Begriche, et al.
Advances in pharmacology (2019), pp. 75-107
Open Access | Times Cited: 83
Tropifexor‐Mediated Abrogation of Steatohepatitis and Fibrosis Is Associated With the Antioxidative Gene Expression Profile in Rodents
Eloy D. Hernandez, Lianxing Zheng, Young Ho Kim, et al.
Hepatology Communications (2019) Vol. 3, Iss. 8, pp. 1085-1097
Open Access | Times Cited: 79
Deep learning enables pathologist-like scoring of NASH models
Fabian Heinemann, Gerald Birk, Birgit Stierstorfer
Scientific Reports (2019) Vol. 9, Iss. 1
Open Access | Times Cited: 79
New drugs for NAFLD: lessons from basic models to the clinic
Katharina C. Reimer, Alexander Wree, Christoph Roderburg, et al.
Hepatology International (2019) Vol. 14, Iss. 1, pp. 8-23
Closed Access | Times Cited: 79
Single-cell and bulk transcriptomics of the liver reveals potential targets of NASH with fibrosis
Zhongyi Wang, Adrian Keogh, Annick Waldt, et al.
Scientific Reports (2021) Vol. 11, Iss. 1
Open Access | Times Cited: 75
FGF19 and FGF21 for the Treatment of NASH—Two Sides of the Same Coin? Differential and Overlapping Effects of FGF19 and FGF21 From Mice to Human
Emma Henriksson, Birgitte Andersen
Frontiers in Endocrinology (2020) Vol. 11
Open Access | Times Cited: 72
Activation of AMPK by triptolide alleviates nonalcoholic fatty liver disease by improving hepatic lipid metabolism, inflammation and fibrosis
Rongshuang Huang, Fan Guo, Yanping Li, et al.
Phytomedicine (2021) Vol. 92, pp. 153739-153739
Closed Access | Times Cited: 66
Genetic and Diet-Induced Animal Models for Non-Alcoholic Fatty Liver Disease (NAFLD) Research
Christina‐Maria Flessa, Narjes Nasiri‐Ansari, Ioannis Kyrou, et al.
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 24, pp. 15791-15791
Open Access | Times Cited: 65
Targeting a novel inducible GPX4 alternative isoform to alleviate ferroptosis and treat metabolic-associated fatty liver disease
Jie Tong, Dongjie Li, Hongbo Meng, et al.
Acta Pharmaceutica Sinica B (2022) Vol. 12, Iss. 9, pp. 3650-3666
Open Access | Times Cited: 63
Exploring the potential mechanism of Rhodomyrtus tomentosa (Ait.) Hassk fruit phenolic rich extract on ameliorating nonalcoholic fatty liver disease by integration of transcriptomics and metabolomics profiling
Ruimin Wang, Linling Yao, Xue Lin, et al.
Food Research International (2021) Vol. 151, pp. 110824-110824
Closed Access | Times Cited: 56
Nonalcoholic steatohepatitis and mechanisms by which it is ameliorated by activation of the CNC-bZIP transcription factor Nrf2
Boushra Bathish, Holly Robertson, John Dillon, et al.
Free Radical Biology and Medicine (2022) Vol. 188, pp. 221-261
Open Access | Times Cited: 50
Induction of Accelerated Aging in a Mouse Model
Nanshuo Cai, Yifan Wu, Yan Huang
Cells (2022) Vol. 11, Iss. 9, pp. 1418-1418
Open Access | Times Cited: 42
Reverse pharmacology of Nimbin-N2 attenuates alcoholic liver injury and promotes the hepatoprotective dual role of improving lipid metabolism and downregulating the levels of inflammatory cytokines in zebrafish larval model
Gokul Sudhakaran, Pandurangan Prathap, Ajay Guru, et al.
Molecular and Cellular Biochemistry (2022) Vol. 477, Iss. 10, pp. 2387-2401
Closed Access | Times Cited: 40
DT-109 ameliorates nonalcoholic steatohepatitis in nonhuman primates
Pengxiang Qu, Oren Rom, Ke Li, et al.
Cell Metabolism (2023) Vol. 35, Iss. 5, pp. 742-757.e10
Open Access | Times Cited: 36
The genetic background shapes the susceptibility to mitochondrial dysfunction and NASH progression
Giorgia Benegiamo, Giacomo von Alvensleben, Sandra Rodríguez-López, et al.
The Journal of Experimental Medicine (2023) Vol. 220, Iss. 4
Open Access | Times Cited: 29
Obesity, non-alcoholic fatty liver disease and hepatocellular carcinoma: current status and therapeutic targets
Yinshuang Chen, Weipeng Wang, Maria P. Morgan, et al.
Frontiers in Endocrinology (2023) Vol. 14
Open Access | Times Cited: 27
The interplay between nonalcoholic fatty liver disease and atherosclerotic cardiovascular disease
Alexandra C Finney, Sandeep R. Das, Dhananjay Kumar, et al.
Frontiers in Cardiovascular Medicine (2023) Vol. 10
Open Access | Times Cited: 21
Microbiota modulation by dietary oat beta-glucan prevents steatotic liver disease progression
J. Jaeger, Annette Brandt, Wenfang Gui, et al.
JHEP Reports (2024) Vol. 6, Iss. 3, pp. 100987-100987
Open Access | Times Cited: 8
Ginsenoside Rg1 Protects against Non-alcoholic Fatty Liver Disease by Ameliorating Lipid Peroxidation, Endoplasmic Reticulum Stress, and Inflammasome Activation
Yashu Xu, Cheng Yang, Shujun Zhang, et al.
Biological and Pharmaceutical Bulletin (2018) Vol. 41, Iss. 11, pp. 1638-1644
Open Access | Times Cited: 81
Role of Innate Immune Signaling in Non-Alcoholic Fatty Liver Disease
Jingjing Cai, Xiao‐Jing Zhang, Hongliang Li
Trends in Endocrinology and Metabolism (2018) Vol. 29, Iss. 10, pp. 712-722
Closed Access | Times Cited: 78
The transcription factor c-Jun/AP-1 promotes liver fibrosis during non-alcoholic steatohepatitis by regulating Osteopontin expression
Isabel Schulien, Birgit Hockenjos, Annette Schmitt‐Graeff, et al.
Cell Death and Differentiation (2019) Vol. 26, Iss. 9, pp. 1688-1699
Open Access | Times Cited: 74
Pathogenesis of Nonalcoholic Steatohepatitis and Hormone-Based Therapeutic Approaches
Kook Hwan Kim, Myung‐Shik Lee
Frontiers in Endocrinology (2018) Vol. 9
Open Access | Times Cited: 67
Comparison of murine steatohepatitis models identifies a dietary intervention with robust fibrosis, ductular reaction, and rapid progression to cirrhosis and cancer
Guangyan Wei, Ping An, Kahini A. Vaid, et al.
AJP Gastrointestinal and Liver Physiology (2019) Vol. 318, Iss. 1, pp. G174-G188
Open Access | Times Cited: 64

Scroll to top